Skip to main content

Transient Ischemic Attack clinical trials at University of California Health

4 in progress, 2 open to eligible people

Showing trials for
  • Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis

    open to eligible people ages 30 years and up

    An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.

    at UCLA

  • Somatic Dysfunction in Patients With Acute Cerebrovascular Disease

    open to eligible people ages 18 years and up

    The goals of this observational study are to test the reliability of a new, standardized physical examination method to identify motion problems within joints or groups of joints among adult asymptomatic volunteers and in patients hospitalized with stroke or stroke-like episodes (e.g., transient ischemic attack, TIA). The main questions this investigation aims to answer are: - Can different, independent providers reliability quantify motion pattern problems using a systematic approach called, The Functional Pathology of the Musculoskeletal System (FPMSS) model? - Are there differences in joint(s) motion patterns among asymptomatic volunteers, patients with TIA (people with brain disease without new neurologic disability), and recent ischemic stroke (patients with new stroke-related-disability, e.g., paralysis)? - Is there an association between joint(s) motion impairment severity and stroke survivor outcomes? Participants (asymptomatic and those with stroke) will undergo a set of repeated paired, musculoskeletal physical exams by independent providers blinded to each other's assessments and patient information. Researchers will compare the severity, location, and quantity of joint(s) motion impairment between these three groups with the physical examination methodology (FPMSS). Clinical information (e.g., test results, diagnoses, brain imaging, medical history) will be collected from patients admitted for TIA and stroke. Enrolled participants with recent stroke will complete a survey three months after hospitalization to determine their self-perceived quality-of-life.

    at UC Davis

  • Cilostazol for Prevention of Recurrent Stroke Trial

    Sorry, not yet accepting patients

    The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months. To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it. Participants will: - Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine. - Not know which one they are taking, and neither will the study team, which keeps the results fair. - Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding.

    at UCSD

  • Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

    at UC Davis UC Irvine UCLA

Our lead scientists for Transient Ischemic Attack research studies include .

Last updated: